

Cangene Corporation Investor Fact Sheet Q2 2010

Corporate Profile

Led by our experienced senior management team, Cangene posted record revenues and record profits in 2009—an impressive feat given the challenging economic climate.

Recognizing the extraordinary power of antibodies and the immune system, Cangene has been developing, manufacturing and selling hyperimmune therapeutics for nearly thirty years. Most recently, our new products have been aimed at infectious disease and biodefence targets such as hepatitis B, botulism and anthrax. We have five products that have been approved in the United States and/or Canada, and three of our products have been accepted into the U.S. Strategic National Stockpile.

Our business is divided into two operating segments. The core commercial biopharmaceutical product segment provides revenue from approved product sales. The contract-services business is dominated by large government biodefence contracts and generates a somewhat uneven revenue stream that nevertheless adds significant upside as product is delivered.

Cangene has been listed on the Toronto Stock Exchange since 1991 under the symbol CNJ. We have operations in Manitoba and Ontario in Canada, and in California, Maryland and Florida in the United States. The majority of our 700 employees work in Winnipeg or at Cangene bioPharma, Inc., our subsidiary in Baltimore. Additional company information can be found at www.cangene.com and www.cangenebiopharma.com.

Recent Events at a Glance

- Signed new agreement with Apotex—obtained rights to certain recombinant protein products; royalties received from sales of Apotex's deferiprone will phase out over three fiscal years
- HepaGam B® approved in Canada for post-exposure prophylaxis indication; full Notice of Compliance with no conditions
- New, Normal Course Issuer Bid commenced
- Entered agreement with Maxygen, Inc. for exclusive option to obtain an exclusive licence to its MAXY-G34 protein for use in treating acute radiation syndrome ("ARS")
- Submitted bid to the BARDA office of the U.S. Department of Health and Human Services to develop a therapeutic for treating ARS
- HepaGam B® approved in Israel for both its indications; first non-North American approval
- Acquired biotechnology company, Twinstrand Therapeutics Inc.
- Announced exit from European market with WinRho® SDF for both its indications
- Signed supply agreement for VIG and BAT products with new, international customer; first non-U.S. sale of BAT
- Amended Normal Course Issuer Bid to increase maximum number of shares
- Building U.S. sales force within Cangene bioPharma, Inc. (formerly Chesapeake Biological Laboratories, Inc.) to focus on commercialization of HepaGam B® in U.S.
- Received positive opinion from European Medicines Agency regarding ImmunoGam™ [Human Hepatitis B Immunoglobulin]; the product known as HepaGam B® in North America

Selected Corporate Information

Fiscal Year End: July 31 Trading Symbol: CNJ (TSX)

At March 16, 2010:

■ Close	C\$5.09
■ Market Cap.	C\$347 million
■ 52-week range	C\$3.84–\$6.41
■ Shares Outstanding	68,246,870
■ Apotex Group ownership	63%



Investor Contact

Ms. Jean Compton, Manager Corporate Communications
Ph. 416-675-8280 e-mail jcompton@cangene.com

Head Office

155 Innovation Drive,
Winnipeg, MB, Canada, R3T 5Y3

Registered Office & Corporate Communications

180 Attwell Drive, Suite 360
Toronto, ON, Canada, M9W 6A9

Cangene bioPharma, Inc.

1111 South Paca Street,
Baltimore, MD, USA, 21230




Cangene Plasma Resources


- Winnipeg, MB, Canada
- Van Nuys, CA, USA
- Altamonte Springs, FL, USA
- Frederick, MD, USA



Revenues




R&D Expenses*




* After applying investment tax credits

Net Income



* Includes an \$18.0-million non-cash impairment loss related to the Cangene bioPharma facility

Net Cash Position*



* Net cash position = cash – debt

“One of the features of Cangene is a clean balance sheet with significant cash reserves and no debt.”

MICHAEL GRAHAM | CHIEF FINANCIAL OFFICER

